David Aviezer

3.1k total citations
34 papers, 2.3k citations indexed

About

David Aviezer is a scholar working on Molecular Biology, Cell Biology and Physiology. According to data from OpenAlex, David Aviezer has authored 34 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Molecular Biology, 16 papers in Cell Biology and 12 papers in Physiology. Recurrent topics in David Aviezer's work include Proteoglycans and glycosaminoglycans research (14 papers), Fibroblast Growth Factor Research (12 papers) and Lysosomal Storage Disorders Research (12 papers). David Aviezer is often cited by papers focused on Proteoglycans and glycosaminoglycans research (14 papers), Fibroblast Growth Factor Research (12 papers) and Lysosomal Storage Disorders Research (12 papers). David Aviezer collaborates with scholars based in Israel, Spain and United States. David Aviezer's co-authors include Avner Yayon, Michal Safran, Yoseph Shaaltiel, Magdalena Eisinger, Guido David, Dalit Hecht, Joel L. Sussman, Israel Silman, Anthony H. Futerman and Sharon Hashmueli and has published in prestigious journals such as Cell, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

David Aviezer

34 papers receiving 2.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David Aviezer Israel	22	1.5k	981	412	403	323	34	2.3k
Adam P. Silverman United States	21	2.3k 1.5×	220 0.2×	239 0.6×	179 0.4×	206 0.6×	36	3.2k
Flavio Curnis Italy	34	2.1k 1.4×	308 0.3×	167 0.4×	125 0.3×	115 0.4×	79	3.9k
Mansoureh Sameni United States	36	1.7k 1.1×	745 0.8×	122 0.3×	168 0.4×	111 0.3×	58	3.7k
Nobuyuki Kurosawa Japan	27	1.9k 1.3×	591 0.6×	67 0.2×	90 0.2×	379 1.2×	76	2.3k
Kamiar Moin United States	30	1.1k 0.7×	404 0.4×	81 0.2×	115 0.3×	105 0.3×	50	2.4k
Sylvain Julien France	24	2.0k 1.3×	314 0.3×	179 0.4×	47 0.1×	413 1.3×	28	2.6k
Jennifer E. Koblinski United States	27	1.3k 0.8×	317 0.3×	116 0.3×	79 0.2×	66 0.2×	71	2.7k
Douglas K. Ferris United States	24	1.8k 1.1×	956 1.0×	47 0.1×	133 0.3×	78 0.2×	54	2.7k
Masanobu Komatsu United States	28	1.7k 1.1×	390 0.4×	39 0.1×	112 0.3×	158 0.5×	66	2.9k
Yutaka Sanai Japan	26	2.1k 1.4×	656 0.7×	27 0.1×	220 0.5×	175 0.5×	67	2.6k

Countries citing papers authored by David Aviezer

Since Specialization

Citations

This map shows the geographic impact of David Aviezer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Aviezer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Aviezer more than expected).

Fields of papers citing papers by David Aviezer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Aviezer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Aviezer. The network helps show where David Aviezer may publish in the future.

Co-authorship network of co-authors of David Aviezer

This figure shows the co-authorship network connecting the top 25 collaborators of David Aviezer. A scholar is included among the top collaborators of David Aviezer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Aviezer. David Aviezer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Shaaltiel, Yoseph, et al.. (2015). Plant‐based oral delivery of β‐glucocerebrosidase as an enzyme replacement therapy for Gaucher's disease. Plant Biotechnology Journal. 13(8). 1033–1040. 40 indexed citations

Kizhner, Tali, Yaniv Azulay, Mariana Hainrichson, et al.. (2014). Characterization of a chemically modified plant cell culture expressed human α-Galactosidase-A enzyme for treatment of Fabry disease. Molecular Genetics and Metabolism. 114(2). 259–267. 94 indexed citations

Dussen, Laura van, Ari Zimran, Erik M. Akkerman, et al.. (2012). Taliglucerase alfa leads to favorable bone marrow responses in patients with type I Gaucher disease. Blood Cells Molecules and Diseases. 50(3). 206–211. 31 indexed citations

Dussen, Laura van, Carla E. M. Hollak, Ari Zimran, et al.. (2012). Long Term Bone Marrow Responses, as Measured by Quantitative Chemical Shift Imaging (QCSI) MRI, Following Treatment With Taliglucerase Alfa in Patients with Type 1 Gaucher Disease. Molecular Genetics and Metabolism. 105(2). S62–S63. 2 indexed citations

Brumshtein, Boris, Matilde Aguilar‐Moncayo, Juan M. Benito, et al.. (2011). Cyclodextrin-mediated crystallization of acid β-glucosidase in complex with amphiphilic bicyclic nojirimycin analogues. Organic & Biomolecular Chemistry. 9(11). 4160–4160. 30 indexed citations

Aviezer, David, et al.. (2010). 9. Novel enzyme replacement therapy for Gaucher disease: Phase III pivotal clinical trial with plant cell expressed recombinantglucocerebrosidase (prGCD) – taliglucerase alpha. Molecular Genetics and Metabolism. 99(2). S9–S10. 8 indexed citations

Brumshtein, Boris, Matilde Aguilar‐Moncayo, M. Isabel García‐Moreno, et al.. (2009). 6‐Amino‐6‐deoxy‐5,6‐di‐N‐(N′‐octyliminomethylidene)nojirimycin: Synthesis, Biological Evaluation, and Crystal Structure in Complex with Acid β‐Glucosidase. ChemBioChem. 10(9). 1480–1485. 45 indexed citations

Aviezer, David, et al.. (2008). 6. Novel enzyme replacement therapy for Gaucher disease: On-going phase III clinical trial with recombinant human glucocerebrosidase expressed in plant cells. Molecular Genetics and Metabolism. 93(2). 15–15. 20 indexed citations

Brumshtein, Boris, Harry M. Greenblatt, Terry D. Butters, et al.. (2007). Crystal Structures of Complexes of N-Butyl- and N-Nonyl-Deoxynojirimycin Bound to Acid β-Glucosidase. Journal of Biological Chemistry. 282(39). 29052–29058. 100 indexed citations

10.

Shaaltiel, Yoseph, Daniel Bartfeld, Sharon Hashmueli, et al.. (2007). Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher's disease using a plant cell system. Plant Biotechnology Journal. 5(5). 579–590. 277 indexed citations

11.

Aviezer, David, Myriam Golembo, & Avner Yayon. (2003). Fibroblast Growth Factor Receptor-3 as a Therapeutic Target for Achondroplasia - Genetic Short Limbed Dwarfism. Current Drug Targets. 4(5). 353–365. 49 indexed citations

12.

Landau, Zvi, et al.. (2001). Heparin‐like inhibitory activity to fibroblast growth factor‐2 in wound fluids of patients with chronic skin ulcers and its modulation during wound healing. Wound Repair and Regeneration. 9(4). 323–328. 7 indexed citations

13.

Aviezer, David, Andrew P. Seddon, Mary Jo Wildey, Peter Böhlen, & Avner Yayon. (2001). Development of a High Throughput Screening Assay for Inhibitors of Fibroblast Growth Factor-Receptor-Heparin Interactions. SLAS DISCOVERY. 6(3). 171–177. 4 indexed citations

14.

Aviezer, David, Seonaidh Cotton, M David, et al.. (2000). Porphyrin analogues as novel antagonists of fibroblast growth factor and vascular endothelial growth factor receptor binding that inhibit endothelial cell proliferation, tumor progression, and metastasis.. PubMed. 60(11). 2973–80. 114 indexed citations

15.

Aviezer, David, Michal Safran, & Avner Yayon. (1999). Heparin Differentially Regulates the Interaction of Fibroblast Growth Factor-4 with FGF Receptors 1 and 2. Biochemical and Biophysical Research Communications. 263(3). 621–626. 20 indexed citations

16.

Aviezer, David, Renato V. Iozzo, Douglas M. Noonan, & Avner Yayon. (1997). Suppression of Autocrine and Paracrine Functions of Basic Fibroblast Growth Factor by Stable Expression of Perlecan Antisense cDNA. Molecular and Cellular Biology. 17(4). 1938–1946. 96 indexed citations

17.

Seddon, Andrew P., et al.. (1995). Engineering of Fibroblast Growth Factor: Alteration of Receptor Binding Specificity. Biochemistry. 34(3). 731–736. 23 indexed citations

18.

Aviezer, David, Dalit Hecht, Michal Safran, et al.. (1994). Perlecan, basal lamina proteoglycan, promotes basic fibroblast growth factor-receptor binding, mitogenesis, and angiogenesis. Cell. 79(6). 1005–1013. 451 indexed citations

19.

Safran, Michal, et al.. (1994). Diminished Heparin Binding of a Basic Fibroblast Growth Factor Mutant Is Associated with Reduced Receptor Binding, Mitogenesis, Plasminogen Activator Induction, and in vitro Angiogenesis. Biochemistry. 33(36). 10999–11007. 54 indexed citations

20.

Aviezer, David, Michal Safran, C M Svahn, et al.. (1994). Differential structural requirements of heparin and heparan sulfate proteoglycans that promote binding of basic fibroblast growth factor to its receptor.. Journal of Biological Chemistry. 269(1). 114–121. 222 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact